Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | Journal of Autoimmune Diseases

Figure 2

From: Evaluation of antibodies against human HSP60 in patients with MPO-ANCA associated glomerulonephritis: a cohort study

Figure 2

Anti-hHSP60 antibody levels in healthy controls (HC) and in patients with ANCA-associated vasculitis (AAV). Anti-human Heat Shock Protein 60 (anti-hHSP60) antibody levels are not significantly higher in AAV compared to HC (18 AU/mL [0–319] and 18.5 AU [0–98], respectively). Furthermore, anti-hHSP60 antibody levels in patients with PR3- and MPO-ANCA. Anti-hHSP60 are significantly higher in patients with MPO-ANCA compared to PR3-ANCA (32.5 AU [0–319], and 13 AU [0–79], respectively). In patients with MPO-ANCA, anti-hHSP60 antibody level is also significantly higher when compared to HC (P = 0.02), whereas in PR3-ANCA, it is not. Dotted line represents cut-off value; solid line represents median value.

Back to article page